OraSure Technologies (OSUR) Earnings Date & Reports

Key Takeaways

• Total net revenue rose 14% year over year to $30.9 million, with sequential growth of 1%, marking another step in the company's return to growth.
• Diagnostics revenue climbed 16% to $16.8 million, while Sample Management Solutions revenue jumped 21% to $12.5 million.
• GAAP (Generally Accepted Accounting Principles) gross margin expanded to 45.2% from 43.5% a year earlier, and the operating loss narrowed to $13.0 million from $16.1 million.
• The company reported a net loss of $13.1 million, or $0.19 per diluted share, roughly in line with the prior-year quarter.
• Management guided to fourth-quarter 2026 revenue of $30.0 million to $32.0 million, implying continued momentum.
• OraSure ended the quarter with $148 million in cash and cash equivalents and no debt, supporting its innovation and acquisition strategy.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Discover Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.

Earnings Context and Why It Matters

OraSure Technologies' third-quarter 2026 results mark a meaningful milestone in its multi-year transformation. After a challenging 2025 described by management as a "transition year," the company is now demonstrating a return to top-line growth while improving margins. The results matter for investors because they test whether the strategy of decentralizing diagnostics — bringing testing closer to patients — is translating into durable, profitable growth. Revenue gains in both Diagnostics and Sample Management Solutions, alongside gross margin expansion, suggest the turnaround is gaining traction even as the company continues investing heavily in its innovation pipeline, including the Sherlock molecular testing platform and newly acquired products such as Sickle SCAN.

Reported Results

For the third quarter ended September 30, 2026, OraSure Technologies reported total net revenues of $30.9 million, an increase of 14% from $27.1 million in the prior-year period and up 1% sequentially. Core revenue, which excludes COVID-19 and exited business lines, also totaled $30.9 million, up 14% year over year.

By segment, Diagnostics revenue rose 16% to $16.8 million, while Sample Management Solutions revenue increased 21% to $12.5 million. GAAP (Generally Accepted Accounting Principles) gross margin expanded to 45.2%, up from 43.5% a year earlier, reflecting better operational efficiency. The GAAP operating loss narrowed to $13.0 million from $16.1 million in the prior-year quarter.

The company posted a net loss of $13.1 million, or $0.19 per diluted share, compared with a net loss of $13.7 million, or $0.19 per diluted share, a year ago. Results came in ahead of analyst expectations on the bottom line. OraSure also reported initial third-quarter commercial orders for its Colli-Pee Dx urine self-collection device and the OraQuick Ebola 2.0 rapid antigen test. For the fourth quarter of 2026, management guided to revenue of $30.0 million to $32.0 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like OraSure Technologies, it offers a streamlined way to surface new opportunities across industries and strategies.

Market Reaction and Investor Sentiment

Investor reaction to the third-quarter results was measured, with shares holding relatively steady following the release as the market weighed improving revenue growth and margin expansion against a still-negative bottom line. The 14% revenue increase and narrowed operating loss signal that the company's restructuring efforts are producing tangible results, which appeared to reinforce confidence in management's long-term plan. At the same time, the company remains unprofitable as it continues to fund significant innovation investments, and investors are closely watching whether the growth trajectory can be sustained into 2027 and whether new product launches can accelerate the path toward profitability.

Forward Outlook and Key Factors to Monitor

Looking ahead, the fourth-quarter revenue guidance of $30.0 million to $32.0 million suggests management expects the return to growth to continue through the end of 2026. Investors should watch whether OraSure can maintain its gross margin expansion as it scales volumes, since a stated long-term goal is to move toward a 50% adjusted gross margin.

Several catalysts are worth monitoring. The company is advancing regulatory and commercial milestones across its innovation pipeline, including the InteliQuick CT/NG (chlamydia and gonorrhea) molecular self-test on the Sherlock platform and the Colli-Pee Dx urine collection device. Early commercial orders for these products are a positive signal, but broader adoption will depend on regulatory approvals and customer uptake.

On the international side, OraSure continues to diversify beyond its core HIV (human immunodeficiency virus) testing franchise, with Sickle SCAN expansion across Africa and the potential of the OraQuick Ebola 2.0 test. The outcome of independent studies and regional recommendations could influence future demand. Balance-sheet strength — $148 million in cash and no debt — gives management flexibility to pursue additional acquisitions and partnerships, though continued investment in research and development will likely keep near-term profitability under pressure. Investors should focus on revenue momentum, margin trends, and the timing of new product launches as the company works toward its 2027 growth objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations